Ubs Oconnor LLC Reata Pharmaceuticals Inc Transaction History

Ubs Oconnor LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$79.22 - $105.37 $396,100 - $526,850	5,000 New	5,000 $510 Million
Q1 2023 May 15, 2023	BUY	$30.85 - $93.17 $161,962 - $489,142	5,250 New	5,250 $477,000
Q4 2018 Feb 15, 2019	BUY	$48.76 - $76.44 $237,656 - $372,568	4,874 Added 39.61%	17,178 $963,000
Q3 2018 Nov 14, 2018	SELL	$35.64 - $92.06 $2.53 Million - $6.54 Million	-71,060 Reduced 85.24%	12,304 $0
Q3 2017 Nov 14, 2017	BUY	$26.29 - $31.88 $2.19 Million - $2.66 Million	83,364	83,364 $0

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.